- Home
- GNL vs BEAM Comparison
GNL vs BEAM Comparison
Compare GNL & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- BEAM
- Stock Information
- Founded
- GNL 2011
- BEAM 2017
- Country
- GNL United States
- BEAM United States
- Employees
- GNL N/A
- BEAM N/A
- Industry
- GNL Real Estate Investment Trusts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNL Real Estate
- BEAM Health Care
- Exchange
- GNL Nasdaq
- BEAM Nasdaq
- Market Cap
- GNL 1.7B
- BEAM 1.8B
- IPO Year
- GNL N/A
- BEAM 2020
- Fundamental
- Price
- GNL $7.76
- BEAM $15.83
- Analyst Decision
- GNL Buy
- BEAM Strong Buy
- Analyst Count
- GNL 4
- BEAM 11
- Target Price
- GNL $9.50
- BEAM $48.90
- AVG Volume (30 Days)
- GNL 1.5M
- BEAM 2.0M
- Earning Date
- GNL 05-07-2025
- BEAM 05-06-2025
- Dividend Yield
- GNL 13.08%
- BEAM N/A
- EPS Growth
- GNL N/A
- BEAM N/A
- EPS
- GNL N/A
- BEAM N/A
- Revenue
- GNL $789,545,000.00
- BEAM $63,578,000.00
- Revenue This Year
- GNL N/A
- BEAM N/A
- Revenue Next Year
- GNL N/A
- BEAM $10.59
- P/E Ratio
- GNL N/A
- BEAM N/A
- Revenue Growth
- GNL 38.85
- BEAM N/A
- 52 Week Low
- GNL $6.51
- BEAM $13.53
- 52 Week High
- GNL $9.11
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- GNL 51.02
- BEAM 36.15
- Support Level
- GNL $7.48
- BEAM $16.61
- Resistance Level
- GNL $7.95
- BEAM $17.47
- Average True Range (ATR)
- GNL 0.15
- BEAM 0.91
- MACD
- GNL -0.01
- BEAM -0.08
- Stochastic Oscillator
- GNL 40.15
- BEAM 12.63
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.